A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to accelerate the development of better treatment regimens for tuberculosis.
A new system can accurately assess the chromosomal status of in vitro-fertilized embryos using only time-lapse video images of the embryos and maternal age, according to a study from investigators at Weill Cornell Medicine.
Weill Cornell Medicine and the Cornell Jeb E. Brooks School of Public Policy have established the Cornell Health Policy Center to serve as the locus for health policy impact, research and training across Cornell.
A new study from Weill Cornell Medicine researchers helps explain why having ApoE4 – the gene variant most closely linked to Alzheimer’s disease – increases the risk of neurodegeneration and white matter damage.
About half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators.
A study from Weill Cornell Medicine provides new insights into a pair of proteins and their opposing functions in regulating the interferon response in hepatic stellate cells, a critical immune component in the liver’s fight against tumors.
Researchers have used a cutting-edge model system to uncover the mechanism by which SARS-CoV-2 induces new cases of diabetes and worsens complications in people who already have it.
Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to discovering new methods for diagnosing the disease and potential therapies.
Study opens the door to exploring new targets for therapies for fibrolamellar carcinoma, which does not respond to conventional treatments and leaves patients with approximately a year to live on average once it is detected.